Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Jodie Pope Morrison | CEO & Director | 852.63k | -- | 1976 |
| Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer & President of Research | 619.93k | -- | 1961 |
| Dr. Jason A. Campagna M.D., Ph.D. | Chief Medical Officer | 680.93k | -- | 1967 |
| Mr. Lee H. Kalowski M.B.A. | CFO & President | -- | -- | 1981 |
| Dr. Saul W. Fink Ph.D. | Chief Technology Officer | -- | -- | -- |
| Mr. David Appugliese J.D. | Senior VP & Head of People | -- | -- | -- |
| Ms. Maria Marzilli M.P.H. | Executive Vice President of Corporate Strategy & Program Operations | -- | -- | -- |
| Ms. Kathryn E. Golden M.B.A. | Head of Chemistry, Manufacturing & Controls | -- | -- | -- |
Q32 Bio Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 42
Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase 2a clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. It is also discovering and developing the ADX-096, a C3d CR1 fusion protein, and other earlier stage assets, including C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Q32 Bio Inc. Earnings Date
Recent Events
April 25, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission